Healthy volunteers needed to compare generic vs. brand cabergoline

NCT ID NCT07008417

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks if a new version of cabergoline tablets works the same as the standard version in 72 healthy Chinese adults aged 18-45. Participants take one dose of each version under fasting or after a meal, with blood tests to measure drug levels. The goal is to confirm bioequivalence, not to treat any condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERPROLACTINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhejiang Xiaoshan Hospital

    Hangzhou, Zhejiang, 200233, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.